Sarilumab and tocilizumab are equally effective in reducing organ support duration and death in patients who are critically ill with COVID-19.

A 470% increase in OSA incidence over 15 years in Finland was linked to a 10,602% increase in remote care and a 2146% increase in nurse visits.

The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.